Burkitt Lymphoma
📧 Sign up to get email alerts when something new happens for Burkitt Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]
This document outlines a Phase 1/2 clinical trial (ViPOR) evaluating a combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and l…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes autologous stem cell transplant followed by polatuzumab vedotin for patients with various B-cell…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) [Phase 1, Phase 2]
Substudy 01A of MK-9999-01A (LIGHTBEAM-U01) evaluates Zilovertamab Vedotin in pediatric and young adult participants with hematologic malign…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene [Phase 1, Phase 2]
An NCI-sponsored clinical trial is evaluating the safety of CX-5461 (Pidnarulex) in lymphomas with MYC alterations, including Burkitt lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations [Phase 2]
Phase 2 study of CPI-613 (devimistat) for relapsed or refractory Burkitt lymphoma/leukemia and high-grade B-cell lymphoma with high-risk tra…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies [Phase 2]
Phase 2 trial of Brexucabtagene Autoleucel in adults with rare B-cell malignancies has been terminated with results posted.
-
CLINICAL_TRIALS guidance · 2026-03-02Clinical Trial Update: Recommendations for the Treatment of Children With Burkitt's Lymphoma
Clinical trial update providing recommendations for the treatment of children with Burkitt lymphoma.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies [Phase 2]
Phase 2 clinical trial update describing a donor stem cell transplant conditioning regimen with treosulfan, fludarabine, and total-body irra…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma [Phase 1]
Phase 1 trial update of ViPOR-P (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in combination with polatuzumab for relapsed…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT [NA]
Clinical trial update indicates ongoing recruitment for a study evaluating CD45RA-depleted peripheral stem cell addback to prevent viral or …
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas [Phase 1]
Phase 1 trial evaluating pomalidomide with dose-adjusted EPOCH, with or without rituximab, for HIV-associated lymphomas; recruitment is ongo…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia [Phase 2]
Phase 2 clinical trial update describing a combination chemotherapy regimen for relapsed or refractory acute lymphoblastic leukemia, lymphob…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS withdrawal · 2026-01-30Clinical Trial Update: Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab, Venetoclax, and Bortezomib for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recr…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 trial evaluating rapamycin added to high-dose etoposide and cytarabine in relapsed/refractory aggressive lymphoid malignancies; th…
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies [Phase 1]
Phase 1 trial update examining loncastuximab tesirine with DA-EPOCH-R for previously untreated aggressive B-cell lymphoid malignancies; the …
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…